The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

NCT04414579 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Faster Insulin Aspart (Fiasp®)

Sponsor

Mountain Diabetes and Endocrine Center